Journal
VIRUSES-BASEL
Volume 7, Issue 9, Pages 4960-4977Publisher
MDPI
DOI: 10.3390/v7092854
Keywords
hepatitis B virus; anti-HBV drugs; research and development; guidelines
Categories
Funding
- Natural Science Foundation of China [81470852]
- Science and Technology Commission of Shanghai Science and Technology support project [13431900503]
- Medical and Technology Across project of Shanghai Jiao Tong University [YG2012MS02]
- Young Talents Plan of the Shanghai Health System [XYQ2013091]
Ask authors/readers for more resources
Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which represents a significant challenge to public health. The current goal in treating chronic HBV infection is to block progression of HBV-related liver injury and inflammation to end-stage liver diseases, including cirrhosis and hepatocellular carcinoma, because we are unable to eliminate chronic HBV infection. Available therapies for chronic HBV infection mainly include nucleos/tide analogues (NAs), non-NAs, and immunomodulatory agents. However, none of them is able to clear chronic HBV infection. Thus, a new generation of anti-HBV drugs is urgently needed. Progress has been made in the development and testing of new therapeutics against chronic HBV infection. This review aims to summarize the state of the art in new HBV drug research and development and to forecast research and development trends and directions in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
